Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceutical Drug Discovery & Development_Artificial Intelligence (AI) & Machine Learning (ML)
CytoReason

Organization & Developments: CytoReason

Parents

2022: CytoReason, Pfizer ink $110M, 5-year extension of AI-powered drug development deal
CytoReason is a leading technology company developing computational disease models.
The company collects proprietary data from pharmaceutical companies and uses it to simulate human diseases – tissue by tissue, cell by cell.
To date, five of the world's top ten pharma companies use CytoReason's technology. For more information
With CytoReason's massive database and AI-led platform, pharma and biotech companies can identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of approval.